<img src="https://ml.globenewswire.com/Resource/Download/d65cf3f8-cf9c-475c-b740-09a659269da4?size=2" nborder="0" align="left" hspace="5" vspace="5" title="NETRAMARK_WORD_EYE_BLK.jpg" alt="NetraMark Holdings Inc."/>TORONTO, June 09, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced that senior management will deliver a corporate presentation at the Sidoti Small Cap Conference on June 18, 2026, at 9:15 am ET. Interested parties can access the live presentation through the following link: <a href="https://www.globenewswire.com/Tracker?data=oZxnyyxmH4mzOiXakKWeioP9mUjoKDxIngIbjjKxQGLBK-IXi3iRIaJI_KJcWJWr29R0M2VhGmp_RZo_tDBlcUXYq1cw87Urn2l_1rjYR2HRXTf1CKnNuDvUemxuUat3v1sDTnG-wXjQSvQfP1OeEI4ZqbYQtnA2u7tQenn0P1k=" rel="nofollow" target="_blank" title="">Access Live Presentation</a> The Company will also participate in one-on-one meetings at the virtual event on June 17th and June 18th, 2026. During the corporate presentation, NetraMark Chief Executive Officer, George Achilleos, intends to discuss the Company’s commercial, clinical, and regulatory progress with respect to NetraAI, its proprietary AI platform. NetraAI has the potential to identify specific patients driving the outcome of a clinical trial, revealing who has a higher likelihood of response to a drug in clinical development and who does not. About NetraAI NetraAI is engineered to include focus mechanisms that separate small datasets into explainable and unexplainable subsets. Unexplainable subsets are collections of patients that can lead to suboptimal overfit models and inaccurate insights due to poor correlations with the variables involved. NetraAI uses explainable subsets to derive insights and hypotheses (including factors that influence treatment and placebo responses and adverse events), potentially increasing the likelihood of a clinical trial's success. Many other AI methods lack these focus mechanisms and assign every patient to a class, often leading to "overfitting", which drowns out critical information that could have been used to improve a trial's chance of success. About NetraMark NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as help to classify patients for sensitivity to drugs and/or efficacy of treatment. For further details on the Company please see the Company’s publicly available documents filed on the System for Electronic Document Analysis and Retrieval+ (SEDAR+). Forward-Looking Statements This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation including statements regarding the anticipated application of NetraMark's NetraAI platform to identify specific patients driving the outcome of a clinical trial and to reveal who has a higher likelihood of response to a drug in clinical development, which are based upon NetraMark’s current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR+ at www.sedarplus.com including our Annual Information Form for the year ended September 30, 2025. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information. The Toronto Stock Exchange does not accept responsibility for the adequacy or accuracy of this release. Contact Information: Swapan Kakumanu - CFO | <a href="https://www.globenewswire.com/Tracker?data=x4aE1J965k6aOndirwXdM8nOV_5aP9MvRnifI-5irt23Q5YFSxzctj3BOOuh5XSldozDUR7owVpgrnXhKLNMNt0RWNWR1Edb1fo-5l1t6E8=" rel="nofollow" target="_blank" title="swapan@netramark.com">swapan@netramark.com</a> | 403-681-2549 Or Adam Peeler – Investor Relations | <a href="https://www.globenewswire.com/Tracker?data=voZAPteZu9IyNGIlQnnjyfC7pzoIlRgpO7pgMXWZogqAfKtqwQInwBieG2wzAXEQT3vQAQ2dwRdv3TLzNWPoLBoHPREKKLsGNpi8OFzorNlGCtUYblwPfi5mf0wCUXIz5JPvDPs_27XuMm29f77W8Q==" rel="nofollow" target="_blank" title="adam.peeler@loderockadvisors.com">adam.peeler@loderockadvisors.com</a> | 416-427-1235 LodeRock Advisors 1 Toronto St, Suite 202 Toronto, Ontario M5C 2W4 <img alt="" src='https://ml.globenewswire.com/media/ZTliMDgwYTItODY0OS00MzU4LWEyNzAtNmI3NGRiY2JkMGE2LTEyNzE0MjItMjAyNi0wNi0wOS1lbg==/tiny/NetraMark-Holdings-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn